Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ying Lan, Nan Yang, Yirong Wang, Yan Yang, Min Xu & Qin He. (2023) Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 2093-2103.
Read now
Read now
Enrico de Nigris, Catrin Treharne, Nick Brighton, Ulf Holmgren, Andrew Walker & John Haughney. (2022) Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2987-3000.
Read now
Read now
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Bhavesh Lakhotia, Ronan Mahon, Florian S Gutzwiller, Andriy Danyliv, Ivan Nikolaev & Praveen Thokala. (2020) Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 787-797.
Read now
Read now
Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell & Johanna C. Meyer. (2020) Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 1-26.
Read now
Read now
Martine Hoogendoorn, Isaac Corro Ramos, Michael Baldwin, Laura Luciani, Cecile Fabron, Bruno Detournay & Maureen P M H Rutten-van Mölken. (2019) Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 447-456.
Read now
Read now
Amnon Ariel, Alan Altraja, Andrey Belevskiy, Piotr W Boros, Edvardas Danila, Matjaz Fležar, Vladimir Koblizek, Zvi G Fridlender, Kosta Kostov, Alvils Krams, Branislava Milenkovic, Attila Somfay, Ruzena Tkacova, Neven Tudoric, Ruxandra Ulmeanu & Arschang Valipour. (2018) Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 45-56.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero-Acuña, Eduardo Márquez-Martín, Esther Quintana Gallego, Laura Carrasco-Hernández, Maria Abad Arranz & Francisco Ortega Ruiz. (2017) Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1867-1876.
Read now
Read now
Articles from other publishers (8)
Marc Spielmanns, Sebastian Schildge, Jens Peter Diedrich & Arschang Valipour. (2022) Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment. Clinics and Practice 12:1, pages 46-56.
Crossref
Crossref
Jieun Kang, Jae Seung Lee, Sei Won Lee, Jung Bok Lee & Yeon-Mok Oh. (2021) Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials. Respiratory Research 22:1.
Crossref
Crossref
Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson & Maureen Rutten-van Mölken. (2021) Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open 11:8, pages e049675.
Crossref
Crossref
Tanja Fens, Simon van der Pol, Janwillem W.H. Kocks, Maarten J. Postma & Job F.M. van Boven. (2019) Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health 22:10, pages 1092-1101.
Crossref
Crossref
Renata Szpak, Giovanna Chipon Strapasson, Beatriz Böger, Yanna Dantas Rattmann & Eliane Carneiro Gomes. (2019) Legal demands of the tiotropium bromide for treatment of chronic obstructive pulmonary disease and their financial impact for the State of Paraná, Brazil. Einstein (São Paulo) 18.
Crossref
Crossref
Hannah A. Blair. (2019) Tiotropium/Olodaterol: A Review in COPD. Drugs 79:9, pages 997-1008.
Crossref
Crossref
Eric Derom, Guy G. Brusselle & Guy F. Joos. (2019) The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Therapeutic Advances in Respiratory Disease 13, pages 175346661984342.
Crossref
Crossref
Leif Bjermer, Job F. M. van Boven, Madlaina Costa-Scharplatz, Dorothy L. Keininger, Florian S. Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson & Nicolas Roche. (2017) Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respiratory Research 18:1.
Crossref
Crossref